IMNM Immunome Inc.
Drug Pipeline
| Drug | Stage | Notes |
|---|---|---|
|
IMM-BCP-01
COVID-19
|
Phase 1
Phase 1
|
IND filing due 1H 2021.
|
Latest News
-
View Full Article Hide Full Article
- Antibody cocktail (IMM-BCP-01) is a combination of three antibodies that bind to complementary, non-overlapping regions of the SARS-CoV-2 spike protein.
- Efficacious in Syrian hamsters infected with SARS-CoV-2 (USA-WA1/2020) in both prophylactic and treatment schedules.
- Neutralizes South Africa (B.1.351) and UK (B.1.1.7) in live virus testing; Brazil (P.1) and California (B.1.429, also containing B.1.427 mutations) in pseudovirus testing, all of which are CDC-designated "Variants of Concern."
- Investigational New Drug (IND) Filing planned for late 2Q/early 3Q 2021.
Immunome, Inc. (NASDAQ:IMNM), a biopharmaceutical company that utilizes its patient memory B cell platform to develop antibody therapeutics, announced antibody selection for its IMM-BCP-01 antibody cocktail and shared data showing that IMM-BCP-01 neutralizes CDC SARS-CoV-2 "Variants of Concern" in preclinical testing.
IMM-BCP-01 contains three monoclonal antibodies that bind to non-overlapping regions of the spike protein with picomolar affinity. The antibodies exhibit combinatorial effects in vitro against multiple SARS-CoV-2 variants, including those exhibiting both increased transmission in the United States and resistance to current antibody therapeutics and vaccines. In summary, the Immunome antibodies have shown to be effective against the current SARS-CoV-2 and its variants.
Preclinical testing results:
- In Syrian hamsters infected with live SARS-CoV-2 virus (USA-WA1/2020), IMM-BCP-01 reduced lung viral load as a treatment and prophylaxis.
- Live virus studies demonstrated full neutralization by IMM-BCP-01 of CDC-designated "Variants of Concern," South Africa (B.1.351) and UK (B.1.1.7), as well as the U.S. and European reference strains USA-WA1/2020 and BavPat1/2020.
- Pseudovirus studies demonstrated full neutralization by IMM-BCP-01 of CDC-designated "Variants of Concern," Brazil (P.1) and California (B.1.429, which also contains B.1.427 mutations).
- Mechanistic studies demonstrate the selected antibodies bind not only to SARS-CoV-2 spike proteins with complex mutations, including the UK (B.1.1.7), SA (B.1.351), Brazil (P1/P2) and California (B.1.429/427) variants, but also to those with several individual mutations, including E484Q and L452R, which are associated with the recently emerged double mutant (B.1.617, or the India variant).
- Two of the three selected antibodies bind to areas of the Spike protein that may be resistant to evolutionary change.
- In addition to viral neutralization, the antibodies also demonstrated additional mechanisms in vitro that may be of relevance in viral clearance.
"Put simply, the preclinical results we have shared today bear witness to our discovery engine's ability to rapidly identify powerful and rare antibodies for inclusion in our IMM-BCP-01 antibody cocktail," said Purnanand Sarma, Ph.D., President & CEO of Immunome. "The strength of our data gives us the confidence to continue advancing IMM-BCP-01 towards an IND filing. We believe that a combination of antibodies targeting epitopes conserved across known variants is an important, and potentially necessary, aspect of addressing the mutational drift currently seen with SARS-CoV-2."
"Despite the numerous challenges created by the COVID-19 pandemic, it provided an opportunity to enhance government-industry partnerships to rapidly identify solutions," said Dr. Jason Roos, the Joint Program Executive Officer for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND). "Demonstrating the ability to collect blood from convalescent patients and quickly identify multiple antibodies as preventatives or therapeutics may not only combat the current pandemic, but can also establish a platform to combat future novel viruses. We are very encouraged by the current results of testing and product development."
In July 2020, Immunome was awarded a $13.3 million agreement from the U.S. Department of Defense's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), in collaboration with the Defense Health Agency, to support Immunome's COVID program. The research discussed in this press release is part of that program.
Immunome anticipates filing an IND for its IMM-BCP-001 program in late Q2/early Q3 2021.
About Immunome
Immunome is a biopharmaceutical company that utilizes its proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics that are designed to change the way diseases are treated. The company's initial focus is on developing therapeutics to treat oncology and infectious diseases, including COVID-19. Immunome's proprietary discovery platform identifies novel therapeutic antibodies and their targets by leveraging the highly-educated components of the immune system, memory B cells, from patients whose bodies have learned to fight off their disease. For more information, please visit www.immunome.com.
Forward-Looking Statements
This press release includes certain disclosures that contain "forward-looking statements" intended to qualify for the "safe harbor" from liability established by the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding Immunome's beliefs and expectations regarding the advancement of its oncology and COVID-19 therapeutic antibody programs, execution of its clinical and strategic plans, anticipated upcoming milestones for IMM-BCP-01 and IMM‐ONC‐01, including expectations regarding therapeutic potential and benefits thereof, and IND filings. Forward-looking statements may be identified by the words "anticipate," believe," "estimate," "expect," "intend," "plan," "project," "may," "will," "could," "should," "seek," "potential" and similar expressions. Forward-looking statements are based on Immunome's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, those risks and uncertainties associated with: the impact of the COVID-19 pandemic on Immunome's business, operations, strategy, goals and anticipated milestones; Immunome's ability to execute on its strategy including with respect to the timing of its R&D efforts, IND filings, initiation of clinical studies and other anticipated milestones; the timing and effectiveness of any antibody therapeutics which may be developed by Immunome; Immunome's ability to fund operations; and the additional risks and uncertainties set forth more fully under the caption "Risk Factors" in Immunome's Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (SEC) on March 25, 2021, and elsewhere in Immunome's filings and reports with the SEC. Forward-looking statements contained in this announcement are made as of this date, and Immunome undertakes no duty to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210426005219/en/
-
View Full Article Hide Full Article
Immunome, Inc. (NASDAQ:IMNM), a biopharmaceutical company that utilizes its human memory B cell discovery engine platform to discover and develop first-in-class antibody therapeutics, today announced it has entered into a definitive securities purchase agreement for the sale of its equity securities in a private placement with certain accredited investors for gross proceeds to Immunome of approximately $27 million, before deducting placement agent commissions and other offering expenses.
The agreement provides for the sale of an aggregate of 1,000,000 units at a price of $27.00 per unit. Each unit consists of one share of Immunome's common stock and a warrant to purchase one half of a share of common stock at an exercise price of $45.00.
Ladenburg Thalmann & Co. Inc. acted as Immunome's placement agent in the transaction.
Immunome intends to use the net proceeds to accelerate the development of its oncology and infectious disease portfolio, including COVID-19, and for other general corporate purposes.
The private placement is expected to close on or about April 28, 2021, subject to the satisfaction of customary closing conditions. Additional details regarding the private placement will be included in a Form 8-K to be filed by Immunome with the Securities and Exchange Commission ("SEC").
The securities being sold in the private placement have not been registered under the Securities Act of 1933, as amended, or state securities laws and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. Immunome has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable in connection with the private placement and upon exercise of the warrants.
This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
About Immunome
Immunome is a biopharmaceutical company that utilizes its proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics that are designed to change the way diseases are treated. The company's initial focus is on developing therapeutics to treat oncology and infectious diseases, including COVID-19. Immunome's proprietary discovery engine identifies novel therapeutic antibodies and their targets by leveraging the highly educated components of the immune system, memory B cells, from patients whose bodies have learned to fight off their disease. For more information, please visit www.immunome.com.
Forward-Looking Statements
This press release includes certain disclosures that contain "forward-looking statements" intended to qualify for the "safe harbor" from liability established by the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the anticipated use of proceeds from the private placement, Immunome's beliefs and expectations regarding the advancement of its oncology and COVID-19 therapeutic antibody programs, execution of its clinical and strategic plans, anticipated upcoming milestones for IMM-BCP-01 and IMM‐ONC‐01, including expectations regarding therapeutic potential and benefits thereof, and IND filings. Forward-looking statements may be identified by the words "anticipate," believe," "estimate," "expect," "intend," "plan," "project," "may," "will," "could," "should," "seek," "potential" and similar expressions. Forward-looking statements are based on Immunome's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, those risks and uncertainties associated with: the impact of the COVID-19 pandemic on Immunome's business, operations, strategy, goals and anticipated milestones; Immunome's ability to execute on its strategy including with respect to the timing of its R&D efforts, IND filings, initiation of clinical studies and other anticipated milestones; the timing and effectiveness of any antibody therapeutics which may be developed by Immunome; Immunome's ability to fund operations; and the additional risks and uncertainties set forth more fully under the caption "Risk Factors" in Immunome's Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (SEC) on March 25, 2021, and elsewhere in Immunome's filings and reports with the SEC. Forward-looking statements contained in this announcement are made as of this date, and Immunome undertakes no duty to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210426005237/en/
-
View Full Article Hide Full Article
- Seasoned biopharmaceutical executive with more than 30 years of corporate finance and business strategy experience -
Immunome, Inc. (NASDAQ:IMNM), a biopharmaceutical company that utilizes its human memory B cell discovery engine platform to discover and develop first-in-class antibody therapeutics, today announced the appointment of Corleen Roche as Chief Financial Officer. Ms. Roche is a highly accomplished CFO with an extensive background in corporate finance and strategy in the biopharmaceutical industry, and served most recently as the US CFO for Biogen.
"On behalf of the entire company, I am pleased to welcome Corleen to Immunome and look forward to partnering with her as we grow the company together," said Purnanand Sarma, Ph.D., President and CEO of Immunome. "As we continue our rapid growth into a clinical-stage company, Corleen's significant experience will be integral to our success in furthering our promising portfolio of development candidates. Corleen brings with her a deep understanding of financial strategy, capital markets, and business development and I am thrilled that Immunome will benefit from her business and financial acumen."
"I would like to thank Sarma and the Immunome team for welcoming me to the company," said Corleen Roche, Chief Financial Officer of Immunome. "I was drawn to Immunome by the promise of the company's proprietary human memory B cell platform, as well as the quality of the team overseeing its deployment. I look forward to leveraging my financial expertise to progress the company's development plans and help Immunome achieve its full potential."
Corleen Roche is a corporate finance and business strategist with extensive executive experience in the biopharmaceutical industry. Prior to her most recent role as the U.S. CFO for Biogen, Ms. Roche was a CFO at various biopharmaceutical companies including Sandoz, IoGenetics Inc, and Wyeth Pharmaceuticals.
Ms. Roche received a Bachelor of Science in Accountancy from Villanova University.
About Immunome
Immunome is a biopharmaceutical company that utilizes its proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics that are designed to change the way diseases are treated. The company's initial focus is on developing therapeutics to treat oncology and infectious diseases, including COVID-19. Immunome's proprietary discovery engine identifies novel therapeutic antibodies and their targets by leveraging the highly educated components of the immune system, memory B cells, from patients whose bodies have learned to fight off their disease. For more information, please visit www.immunome.com.
Forward-Looking Statements
This press release includes certain disclosures that contain "forward-looking statements" intended to qualify for the "safe harbor" from liability established by the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding Immunome's beliefs and expectations regarding the advancement of its oncology and COVID-19 therapeutic antibody programs, execution of its clinical and strategic plans, anticipated upcoming milestones for IMM-BCP-01 and IMM‐ONC‐01, including expectations regarding therapeutic potential and benefits thereof, and IND filings. Forward-looking statements may be identified by the words "anticipate," believe," "estimate," "expect," "intend," "plan," "project," "may," "will," "could," "should," "seek," "potential" and similar expressions. Forward-looking statements are based on Immunome's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, those risks and uncertainties associated with: the impact of the COVID-19 pandemic on Immunome's business, operations, strategy, goals and anticipated milestones; Immunome's ability to execute on its strategy including with respect to the timing of its R&D efforts, IND filings, initiation of clinical studies and other anticipated milestones; the timing and effectiveness of any antibody therapeutics which may be developed by Immunome; Immunome's ability to fund operations; and the additional risks and uncertainties set forth more fully under the caption "Risk Factors" in Immunome's Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (SEC) on March 25, 2021, and elsewhere in Immunome's filings and reports with the SEC. Forward-looking statements contained in this announcement are made as of this date, and Immunome undertakes no duty to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210420005284/en/
-
View Full Article Hide Full Article
- Pharmaceutical industry veteran brings more than three decades of experience developing innovative therapies -
Immunome, Inc. (NASDAQ:IMNM), a biopharmaceutical company that utilizes its human memory B cell discovery engine platform to discover and develop first-in-class antibody therapeutics, today announced the appointment of Dennis Giesing, Ph.D., to the role of Chief Development Officer (CDO). In this position, Dr. Giesing will lead Immunome's product development, clinical and regulatory strategy and drive the progression of the company's pipeline.
"I am pleased to welcome Dennis to the Immunome team. With two IND filings planned for 2021, Dennis joins our company at an exciting time, and we look forward to leveraging his extensive experience to further our pipeline candidates through their next stages of development," said Purnanand Sarma, Ph.D., President and CEO of Immunome. "Dennis brings a deep and unique combination of skills and expertise across multiple therapeutic areas, including oncology, inflammation and anti-infectives, and I am confident he will be a great asset for our company."
"I am excited to join Immunome and particularly impressed by the potential of the company's human memory B cell discovery engine and its capacity to generate unique development candidates," said Dennis Giesing, Ph.D., Chief Development Officer of Immunome. "Harnessing the information stored in human B cells and using it to create novel antibody therapeutics is an incredible breakthrough that I hope to play an integral part in developing fully in my new role."
Dr. Giesing has more than 35 years of pharmaceutical industry experience, and was most recently at Johnson & Johnson Oncology. Prior to that he served as Chief Scientific Officer at Taris Biomedical for nearly 12 years, heading the development of innovative treatments for bladder diseases including overactive bladder and bladder cancer, leading to its acquisition by Johnson & Johnson in 2019. Previously, Dr. Giesing was Head of Pharmaceutical Development at Medivector, leading the development of treatments to combat infectious diseases, including pandemic influenza and hemorrhagic viruses. Before that, he served as Senior Vice President of Lead Optimization at Aventis Pharmaceuticals, advancing novel therapies into late-stage clinical development.
Dr. Giesing received his B.S. in chemistry and a Ph.D. in biochemical pharmacology from the University of Missouri, Kansas City.
About Immunome
Immunome is a biopharmaceutical company that utilizes its proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics that are designed to change the way diseases are treated. The company's initial focus is on developing therapeutics to treat oncology and infectious diseases, including COVID-19. Immunome's proprietary discovery engine identifies novel therapeutic antibodies and their targets by leveraging the highly educated components of the immune system, memory B cells, from patients whose bodies have learned to fight off their disease. For more information, please visit www.immunome.com.
Forward-Looking Statements
This press release includes certain disclosures that contain "forward-looking statements" intended to qualify for the "safe harbor" from liability established by the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding Immunome's beliefs and expectations regarding the advancement of its oncology and COVID-19 therapeutic antibody programs, execution of its clinical and strategic plans, anticipated upcoming milestones for IMM-BCP-01 and IMM‐ONC‐01, including expectations regarding therapeutic potential and benefits thereof, and IND filings. Forward-looking statements may be identified by the words "anticipate," believe," "estimate," "expect," "intend," "plan," "project," "may," "will," "could," "should," "seek," "potential" and similar expressions. Forward-looking statements are based on Immunome's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, those risks and uncertainties associated with: the impact of the COVID-19 pandemic on Immunome's business, operations, strategy, goals and anticipated milestones; Immunome's ability to execute on its strategy including with respect to the timing of its R&D efforts, IND filings, initiation of clinical studies and other anticipated milestones; the timing and effectiveness of any antibody therapeutics which may be developed by Immunome; Immunome's ability to fund operations; and the additional risks and uncertainties set forth more fully under the caption "Risk Factors" in Immunome's Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (SEC) on March 25, 2021, and elsewhere in Immunome's filings and reports with the SEC. Forward-looking statements contained in this announcement are made as of this date, and Immunome undertakes no duty to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210330005204/en/
-
View Full Article Hide Full Article
- IMM-BCP-01: Isolated antibodies capable of neutralizing SARS-CoV-2 variants, including the South African variant (B.1.351), in pseudovirus testing -
- IMM-ONC-01: Advanced proprietary antibody against IL-38 into IND-enabling studies -
- Raised $44.9 million in gross proceeds in NASDAQ IPO -
- Program updates expected in 2Q 2021 -
Immunome, Inc. (NASDAQ:IMNM), a biopharmaceutical company that utilizes its human memory B cell discovery engine platform to discover and develop first-in-class antibody therapeutics, today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided a corporate update.
"The fourth quarter of 2020 was a transformational period for Immunome thanks to our successful initial public offering on the NASDAQ exchange, which raised $44.9 million in gross proceeds," said Purnanand Sarma, Ph.D., President and CEO of Immunome. "That positive momentum continued into 2021, with our recent announcements covering the isolation of antibodies capable of neutralizing SARS-CoV-2 variants in pseudovirus testing as part of our IMM-BCP-01 program, and the advancement of IMM-ONC-01, our proprietary antibody against IL-38 for the potential treatment of solid tumors including malignancies of high unmet need such as cancers of the head and neck and the lung, into IND-enabling studies."
Dr. Sarma continued: "Looking ahead, we expect to provide development program updates in the second quarter of 2021 and to file INDs for both IMM-BCP-01 and IMM-ONC-01 in 2021. We remain excited about the prospects for both of our current development programs and reiterate the confidence we have in our discovery engine to move one to two new candidates into IND-enabling studies per year. I very much look forward to updating you on our progress in the months ahead."
Financial Highlights
- Cash and cash equivalents: As of December 31, 2020, cash and cash equivalents totaled $39.8 million.
- Research and development (R&D) expenses: R&D expenses for the three months ended December 31, 2020 were $1.8 million. R&D expenses for the year ended December 31, 2020 were $7.5 million.
- General and administrative (G&A) expenses: G&A expenses for the three months ended December 31, 2020 were $2.2 million. G&A expenses were $4.8 million for the year ended December 31, 2020.
- Net loss: Net loss attributable to common stockholders was $4.1 million, or $0.40 per share, for the three months ended December 31, 2020. Net loss attributable to common stockholders was $17.8 million, or $5.26 per share, for the year ended December 31, 2020.
- As of December 31, 2020, Immunome had 10,634,245 shares of common stock outstanding.
About Immunome
Immunome is a biopharmaceutical company that utilizes its proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics that are designed to change the way diseases are treated. The company's initial focus is on developing therapeutics to treat oncology and infectious diseases, including COVID-19. Immunome's proprietary discovery engine identifies novel therapeutic antibodies and their targets by leveraging the highly educated components of the immune system, memory B cells, from patients whose bodies have learned to fight off their disease. For more information, please visit www.immunome.com.
Forward-Looking Statements
This press release includes certain disclosures that contain "forward-looking statements" intended to qualify for the "safe harbor" from liability established by the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding Immunome's beliefs and expectations regarding the advancement of its oncology and COVID-19 therapeutic antibody programs, execution of its clinical and strategic plans, anticipated upcoming milestones for IMM-BCP-01 and IMM‐ONC‐01, including expectations regarding therapeutic potential and benefits thereof, and IND filings. Forward-looking statements may be identified by the words "anticipate," believe," "estimate," "expect," "intend," "plan," "project," "may," "will," "could," "should," "seek," "potential" and similar expressions. Forward-looking statements are based on Immunome's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, those risks and uncertainties associated with: the impact of the COVID-19 pandemic on Immunome's business, operations, strategy, goals and anticipated milestones; Immunome's ability to execute on its strategy including with respect to the timing of its R&D efforts, IND filings, initiation of clinical studies and other anticipated milestones; the timing and effectiveness of any antibody therapeutics which may be developed by Immunome; Immunome's ability to fund operations; and the additional risks and uncertainties set forth more fully under the caption "Risk Factors" in Immunome's Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (SEC) on March 25, 2021, and elsewhere in Immunome's filings and reports with the SEC. Forward-looking statements contained in this announcement are made as of this date, and Immunome undertakes no duty to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable law.
IMMUNOME, INC.
Statements of operations
(in thousands, except share and per share amounts)
Three Months Ended December 31,
Year ended December 31,
2020
2019
2020
2019
Operating expenses:
Research and development
$
1,835
$
2,432
$
7,486
$
8,823
General and administrative
2,238
456
4,775
1,525
Total operating expenses
4,073
2,888
12,261
10,348
Loss from operations
(4,073
)
(2,888
)
(12,261
)
(10,348
)
Other expenses:
Change in fair value of warrant liability
11
—
(5,538
)
—
Interest expense, net
(11
)
(34
)
(38
)
(96
)
Total other expenses
-
(34
)
(5,576
)
(96
)
Net loss
$
(4,073
)
$
(2,922
)
$
(17,837
)
$
(10,444
)
Per share information:
Net loss per share of common stock, basic and diluted
$
(0.40
)
$
(2.66
)
$
(5.26
)
$
(9.55
)
Weighted-average common shares outstanding, basic and diluted
10,190,607
1,097,907
3,389,592
1,093,959
IMMUNOME, INC.
Balance sheets
(in thousands, except share and per share amounts)
December 31,
2020
2019
Assets
Current assets:
Cash
$
39,766
$
2,543
Prepaid expenses and other current assets
3,128
579
Total current assets
42,894
3,122
Property and equipment, net
1,531
1,700
Restricted cash
100
100
Other assets
—
138
Total assets
$
44,525
$
5,060
Liabilities, convertible preferred stock, and stockholders' equity (deficit)
Current liabilities:
Current portion of capital lease obligations
$
—
$
239
Current portion of long-term debt
366
—
Current portion of equipment loan payable
113
212
Accounts payable
1,187
548
Accrued expenses and other current liabilities
1,372
666
Total current liabilities
3,038
1,665
Equipment loan payable, net of current portion
—
113
Long-term debt, net of current portion
134
—
Deferred rent
8
18
Total liabilities
3,180
1,796
Series A convertible preferred stock
—
38,894
Stockholders' equity (deficit):
Common stock
1
—
Additional paid-in capital
95,738
927
Accumulated deficit
(54,394)
(36,557)
Total stockholders' equity (deficit)
41,345
(35,630)
Total liabilities, convertible preferred stock, and stockholders' equity (deficit)
$
44,525
$
5,060
View source version on businesswire.com: https://www.businesswire.com/news/home/20210325005954/en/